Erythropoietin


Article Author:
Benjamin Schoener


Article Editor:
Judith Borger


Editors In Chief:
Temekis Hampton


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Kyle Blair
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Daniyal Ameen
Altif Muneeb
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes
Komal Shaheen
Sandeep Sekhon


Updated:
9/7/2019 8:37:08 PM

Indications

Erythropoietin (EPO) is a glycoprotein hormone, naturally produced by the peritubular cells of the kidney, that stimulates red blood cell production. Renal cortex peritubular cells produce most EPO in the human body, though in a fetus, the liver is the primary site of production.[1] EPO production also occurs in the spleen, liver, bone marrow, lung, and brain in small quantities. PO2 directly regulates EPO production. The lower the pO2, the greater the production of EPO. Indirectly, low hemoglobin levels stimulate EPO production. 

Erythropoietin Stimulating Agents (ESA) are recombinant versions of EPO produced pharmacologically. Examples of ESA are epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta.[1]

ESAs are generally indicated in conditions where there is impaired red blood cell production. The two primary FDA approved indications for the use of ESAs are anemia secondary to chronic kidney disease and chemotherapy-induced anemia in cancer patients.[2] Other approved indications are anemia secondary to zidovudine treatment in HIV infection, support in patients receiving autologous blood transfusions, anemic patients undergoing elective surgery (both pre-op and post-op), and anemia in preterm infants.

In CKD, where there is damage to the kidneys and limited EPO production by the peritubular cells, ESAs are beneficial.[3] In CKD, ESAs are useful in patients who are receiving dialysis as well as patients soon to need dialysis. The FDA approved the use of epoetin (1993) and darbepoetin (2002) for patients with chemotherapy-induced anemia. In patients with CKD and chemotherapy-induced anemia, ESAs are generally limited to patients with hemoglobin less than 10g/dL due to the risk of adverse effects.[2]

Mechanism of Action

Endogenous erythropoietin and erythropoietin stimulating agents stimulate division and differentiation of erythroid progenitor cells.[3] The surface of CD34+ hematopoietic stem cells, very early developing erythrocytes, contain EPO receptors. Binding of endogenous EPO or recombinant analogs creates a cellular signaling cascade, activating genes that promote cell proliferation and prevent apoptosis. The result is stimulating an increase in total body hemoglobin and hematocrit.

Administration

Transfected Chinese hamster ovary cells (CHOs) are the usual source for large-scale manufacturing of ESA.[3] An isotonic solution buffers the ESA powder, which the provider can administer intravenously or subcutaneously. Standard dosing for epoetin alfa in patients with anemia secondary to CKD or chemotherapy is 50 to 100 international units per kilogram. This dose is initially given three times weekly. Dosing and frequency can be adjusted based on response to treatment.

Adverse Effects

The most severe adverse effects of EPO are related to a significant risk of thrombotic events, particularly in surgical patients.[3] Supplemental use of ESAs causes an increase in blood viscosity because of a higher rate of erythrocyte production. Given this and given less of a vasodilatory effect due to a low baseline pO2, there is an increased risk of ischemic stroke and myocardial infarction.[4] There is also an increased risk of venous thromboembolism, and some have proposed the use of antithrombotic prophylaxis in patients receiving ESA.[3]

There has been concern regarding the potential progression of tumorigenesis in patients with certain forms of cancer, particularly breast cancer, non-small cell lung cancer, head and neck cancer, lymphoid cancer, and cervical cancer.[5] The mechanism is through increased cell signaling and tumor angiogenesis.

Researchers reported nausea, vomiting, diarrhea, fatigue, insomnia, peripheral edema, thrombocytopenia, myalgias, arthralgias, rashes, abdominal pain, headache, and paresthesias as common adverse effects experienced by patients undergoing chemotherapy who received epoetin alfa in a multicenter study.[6]

Contraindications

ESAs are contraindicated in patients who have hypersensitivity to non-human mammal-derived products because of ESA production methods.[3]

Because of the increase in blood viscosity using ESA, physicians should exercise caution in patients with a history of DVT, pulmonary embolism, or hypercoagulability disorder. Likewise, caution is necessary for patients with a history of ischemic stroke or cardiovascular disease.[4]

ESAs containing benzyl alcohol are contraindicated in neonates, peripartum mothers, and mothers who are breastfeeding due to risk for Gasping syndrome. This syndrome causes gasping respirations, renal failure, and neurological deterioration in neonates, resulting from severe metabolic acidosis.[7]

Monitoring

Patients receiving ESA should have baseline hemoglobin, and transferrin checked before administration.[3] Hemoglobin should be checked frequently at the beginning of treatment weekly. The dosing and frequency of administration should be adjusted based on the response to treatment. If hemoglobin rises to a non-anemic level, the clinician should withhold the ESA.[8] Consider iron supplementation in patients with poor response to therapy as iron availability may be inadequate.[3]

Toxicity

Most cases of ESA toxicity are related to the adverse effects of chronic use. There are few case reports of acute toxicity. One study involves a man who intentionally injected himself with recombinant human erythropoietin, causing his hemoglobin to rise to a dangerously high level.[9] He received treatment with IV fluids, serial phlebotomy, and mechanical ventilation.

Enhancing Healthcare Team Outcomes

Treatment of anemia in patients using erythropoietin stimulating agents (ESA) requires an interprofessional team of medical providers. This team should include a nephrologist in patients with chronic kidney disease, a hematologist/oncologist in patients undergoing chemotherapy, appropriate nursing staff, a pharmacist for ESA dosing, a phlebotomy lab/ technician for blood draws to monitor for improvement.

Appropriate follow-up appointments should be arranged to reassess the patient’s health status and any adverse effects of the ESA; this is where specialty-trained nurses and pharmacists can play a significant role. Nursing will have the most frequent and ongoing contact with the patient, so they can provide education and monitor for adverse effects, as well as administering the medication. Pharmacists with specialty oncology certification should monitor dosing, interactions, and lab values that may alter or stop the dosing of the ESA. Both nurses and pharmacists must chart and inform the treating physician on any findings, changes, or concerns.

Patients should receive counseling on the potential adverse effects and when to seek immediate medical care. Emergency medical providers should be aware of the adverse effects of ESAs to risk-stratify patients for venous thromboembolism, acute coronary syndrome, ischemic stroke, and other emergent conditions related to ESA.

Only through the coordinated effort of an interprofessional healthcare team can ESA therapy be administered safely and effectively, with minimal adverse events and optimal patient results. [Level V]

Monitoring of the hemoglobin level to optimize patient outcomes and minimize adverse effects is very important. A debate exists regarding the appropriate target hemoglobin in individuals treated with ESA. A pooled analysis of nine randomized control trials on patients with chronic kidney disease indicates that patients have higher mortality and morbidity from cardiovascular-related events when the hemoglobin falls below 10 g/dL.[10]In this pooled analysis, there was no benefit in survival in patients treated with ESA when the hemoglobin exceeded 13 g/dL, yet there was a higher incidence of adverse events such as hypertension, vascular access thrombosis, and stroke. Therefore, current guidelines call for individual tailoring of target hemoglobin levels, but optimal levels generally fall between 11 and 12 g/dL with the knowledge that higher doses of ESAs may increase the risk for thrombotic events. [level 1]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Erythropoietin - Questions

Take a quiz of the questions on this article.

Take Quiz
Erythropoietin stimulates which of the following intermediates in hematopoiesis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
The synthesis of erythropoietin occurs in which of the following structures?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which hormone is made in the kidneys?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 65-year-old female with a history of chronic kidney disease is beginning treatment with an erythropoietin stimulating agent (ESA) for the treatment of anemia. Given the mechanism of action and side effect profile, this patient should be counseled on risk for which adverse effect?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 66-year-old male is evaluated in the hospital. He has a history of chronic kidney disease, diabetes mellitus type 2, hypertension, and osteoarthritis. He medications include metformin, losartan, and naproxen. Blood pressure is 128/86 mm Hg, pulse is 81 beats/min, and respiratory rate is 18 breaths/min. A complete blood count shows hemoglobin: 8 g/dl, hematocrit: 31 %, MCV: 80 fL/red cell, platelets: 300,000/microl, and WBC: 9000/ microl. Kidney tests show GFR: 46 mL/min, and greater than 300 mg/g of albumin in the urine. The patient is given a medication to treat his anemia. This medication mimics the action of a hormone synthesized in the interstitial cells of the peritubular capillary bed of the kidney. Which of the following is a potential side effect of this medication?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 1-week-old female is brought to the healthcare provider by her mother with gasping respirations, reduced urine output, and lethargy. Blood urea nitrogen (BUN) is found to be elevated at 45 mg/dL, and creatinine is 4.0 mg/dL. The bicarbonate level is low at 12 mg/dL. while her blood glucose is 90 mg/dL. Further history obtained from the mother reveals that she has been receiving treatment for chronic anemia with erythropoietin, and she has been breast-feeding. What component of this medication is responsible for the patient's presentation?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 65-year-old male with a history of end-stage renal failure presents to the emergency department with sudden onset dyspnea and pleuritic chest pain. He reported compliance with hemodialysis and his last session was one day ago. His heart rate is 115/min, and he has sinus tachycardia with no ischemic findings on EKG. He is tachypneic with a respiratory rate of 24/min, hypoxic with a SpO2 of 88%, his blood pressure is 110/80 mmHg, and he is afebrile. The lungs are clear to auscultation, and he has no stridor. Blood glucose is 90 mg/dl, and hemoglobin is 12.6 g/dL. His chest x-ray reveals a normal-appearing mediastinum, cardiac silhouette, and lung markings with no evidence of fluid overload. Which of the following medications may have contributed to his presentation?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Erythropoietin - References

References

Jelkmann W, Erythropoietin. Frontiers of hormone research. 2016;     [PubMed]
Noxon V,Knopf KB,Norris LB,Chen B,Yang YT,Qureshi ZP,Hrushesky W,Lebby AA,Schooley B,Hikmet N,Dickson M,Thamer M,Cotter D,Yarnold PR,Bennett CL, Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. Journal of oncology practice. 2017 Jun;     [PubMed]
Jelkmann W, Physiology and pharmacology of erythropoietin. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2013 Oct;     [PubMed]
McCullough PA,Barnhart HX,Inrig JK,Reddan D,Sapp S,Patel UD,Singh AK,Szczech LA,Califf RM, Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. American journal of nephrology. 2013;     [PubMed]
Annese T,Tamma R,Ruggieri S,Ribatti D, Erythropoietin in tumor angiogenesis. Experimental cell research. 2019 Jan 15;     [PubMed]
Glaspy JA,Charu V,Luo D,Moyo V,Kamin M,Wilhelm FE, Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer. 2009 Mar 1;     [PubMed]
Gershanik J,Boecler B,Ensley H,McCloskey S,George W, The gasping syndrome and benzyl alcohol poisoning. The New England journal of medicine. 1982 Nov 25;     [PubMed]
Koulouridis I,Alfayez M,Trikalinos TA,Balk EM,Jaber BL, Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013 Jan;     [PubMed]
Brown KR,Carter W Jr,Lombardi GE, Recombinant erythropoietin overdose. The American journal of emergency medicine. 1993 Nov;     [PubMed]
Locatelli F,de Francisco A,Deray G,Fliser D,Armstrong G,Dougherty FC,Ehrhard P, Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron. Clinical practice. 2014;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Nurse-Lab and Diagnostic Testing. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Nurse-Lab and Diagnostic Testing, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Nurse-Lab and Diagnostic Testing, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Nurse-Lab and Diagnostic Testing. When it is time for the Nurse-Lab and Diagnostic Testing board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Nurse-Lab and Diagnostic Testing.